Citigroup
CADL icon

Citigroup’s Candel Therapeutics CADL Stock Holding History

Citigroup’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$105K Buy
21,382
+18,708
+700% +$102K ﹤0.01% 4268
2025
Q4 		$15.1K Buy
2,674
+963
+56% +$5.18K ﹤0.01% 4942
2025
Q3 		$8.73K Sell
1,711
-12,224
-88% -$70.6K ﹤0.01% 5065
2025
Q2 		$70.5K Sell
13,935
-6,303
-31% -$32.4K ﹤0.01% 4586
2025
Q1 		$114K Buy
20,238
+1,635
+9% +$13.4K ﹤0.01% 4521
2024
Q4 		$161K Buy
18,603
+4,113
+28% +$24.3K ﹤0.01% 4543
2024
Q3 		$100K Buy
14,490
+9,892
+215% +$61.5K ﹤0.01% 4760
2024
Q2 		$28.5K Buy
+4,598
New +$34.5K ﹤0.01% 4886
2023
Q3 		– Sell
-118,612
Closed -$149K – 5679
2023
Q2 		$149K Buy
+118,612
New +$175K ﹤0.01% 4036
2023
Q1 		– Sell
-352
Closed -$630 – 5522
2022
Q4 		$630 Buy
352
+17
+5% +$34 ﹤0.01% 5472
2022
Q3 		$1K Sell
335
-95
-22% -$322 ﹤0.01% 5608
2022
Q2 		$1K Sell
430
-180
-30% -$721 ﹤0.01% 5986
2022
Q1 		$3K Sell
610
-256
-30% -$1.27K ﹤0.01% 5945
2021
Q4 		$7K Buy
+866
New +$8.41K ﹤0.01% 5618

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citigroup's CADL Position: Q1 2026 in Review

Citigroup increased its Candel Therapeutics (CADL) stake by 700% in Q1 2026, buying an estimated $102K and bringing the position to 21,382 shares worth $105K. The position accounts for ﹤0.01% of the portfolio, ranked #4268.

Citigroup first reported a position in CADL in Q4 2021 and has held it in 14 quarters since. The position peaked at $161K in Q4 2024. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Citigroup held 21,382 shares of Candel Therapeutics worth $105K as of Q1 2026.
  • Citigroup bought 18,708 Candel Therapeutics shares in Q1 2026, an estimated $102K.
  • Candel Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4268 holding.
  • Citigroup first reported a position in Candel Therapeutics in Q4 2021 and has held it in 14 quarters since.
  • Citigroup's Candel Therapeutics position peaked at $161K in Q4 2024.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.